A study in the September issue of Gastroenterology evaluated the effects of vedolizumab induction therapy for patients with Crohn's disease for whom tumor necrosis factor (TNF) antagonists have already failed.  Dr. Kuemmerle speaks with Dr. Bruce E. Sands

A study in the September issue of Gastroenterology evaluated the effects of vedolizumab induction therapy for patients with Crohn's disease for whom tumor necrosis factor (TNF) antagonists have already failed. Dr. Kuemmerle speaks with Dr. Bruce E. Sands

Vedolizumab for Crohn's Patients After TNF Therapy Has Failed

An engaging, informative mix of author interviews and expert commentary on the latest articles from Gastroenterology, hosted by the AGA journals' online editor, John F. Kuemmerle, MD, AGAF.

Share Vedolizumab for Crohn's Patients After TNF Therapy Has Failed

Sign up to save your podcasts

Vedolizumab for Crohn's Patients After TNF Therapy Has Failed

Vedolizumab for Crohn's Patients After TNF Therapy Has Failed